Veterinary Peptide Drug Development Outsourcing Services: Species-Specific Formulation and INAD/NADA Regulatory Pathways

The Untapped Potential of Peptide Therapeutics in Veterinary Medicine

Peptide therapeutics have advanced human medicine across oncology, endocrinology, metabolic disease, and infectious disease. Yet the veterinary pharmaceutical sector has only begun to explore the potential of peptides as therapeutic agents for companion animals, livestock, and equine patients. This gap represents a significant commercial opportunity for animal health companies willing to invest in veterinary peptide drug development. Explore peptide lyophilization services services.

The biological rationale for veterinary peptide therapeutics is compelling. Many of the molecular targets validated in human medicine, including GLP-1 receptors, somatostatin receptors, melanocortin receptors, and antimicrobial peptide targets, are conserved across mammalian species. Peptides offer advantages that are particularly relevant in veterinary contexts: high target specificity that reduces off-target effects, predictable metabolism that simplifies safety assessment, and the potential for species-specific optimization that can improve efficacy in target animal populations, per FDA drug development.

However, veterinary peptide drug development presents unique challenges that differ substantially from human pharmaceutical development. Species-specific pharmacokinetics, diverse routes of administration, weight-based dosing across breeds that range from Chihuahuas to Great Danes (or from calves to mature bulls), food safety considerations for food-producing animals, and a regulatory pathway governed by the FDA Center for Veterinary Medicine (CVM) rather than CDER all require specialized expertise.

Outsourcing veterinary peptide drug development to contract partners with both peptide science expertise and veterinary pharmaceutical experience allows sponsors to address these challenges without building capabilities that may not exist within their current organization. Explore ocular peptide delivery services.

The global animal health therapeutics market exceeded $45 billion in 2025, yet peptide-based drugs represent less than 2% of approved veterinary pharmaceuticals. This gap is closing as animal health companies recognize the therapeutic potential of peptides for conditions ranging from canine obesity to bovine mastitis.

Species differences in peptide metabolism are not trivial, and formulation strategies that ignore interspecies pharmacokinetic variation will consistently underperform in veterinary clinical trials (Papich, Saunders Handbook of Veterinary Drugs, 2021).

Species-Specific Formulation: The Central Challenge

The most significant technical difference between human and veterinary peptide drug development is the need for species-specific formulation. A peptide that works well in humans may have dramatically different pharmacokinetics in dogs, cats, horses, or cattle due to differences in gastrointestinal physiology, hepatic metabolism, renal clearance, and body composition.

Key species-specific considerations include:

Companion Animals (Dogs and Cats)

• Oral delivery challenges. Dogs and cats have shorter gastrointestinal transit times than humans, which affects the absorption window for oral peptide formulations. Enteric coating strategies and permeation enhancers must be optimized for the specific gastric pH and intestinal environment of each species.
• Weight variability. Dogs range from under 2 kg (toy breeds) to over 80 kg (giant breeds), creating a dosing challenge that requires either weight-banded tablet strengths or concentration-adjustable liquid formulations.
• Palatability. Companion animal formulations must be palatable or amenable to administration via treats, flavored liquids, or other owner-friendly delivery systems. Injectable peptides may be preferred for clinic-administered treatments.
• Feline-specific challenges. Cats are notoriously difficult to medicate orally and have unique hepatic metabolism (limited glucuronidation) that can affect peptide metabolite profiles.

Equine Patients

• Large volume administration. Horses weighing 400 to 600 kg require substantially higher peptide doses, which may necessitate concentrated formulations or alternative delivery routes.
• Intramuscular and subcutaneous depots. Sustained-release formulations that reduce dosing frequency are highly valued in equine practice, where daily injections are impractical for many horse owners.
• Exercise physiology. Peptides targeting musculoskeletal conditions in performance horses must be evaluated under exercise conditions that affect blood flow, tissue distribution, and clearance rates.

Food-Producing Animals (Cattle, Swine, Poultry)

• Withdrawal periods. Peptide drugs administered to food-producing animals must be cleared from edible tissues before slaughter. Establishing appropriate withdrawal periods requires tissue residue depletion studies and analytical methods capable of detecting peptide residues in meat, milk, and eggs.
• Herd/flock treatment economics. The cost per dose must be commercially viable for treating entire herds or flocks, which places constraints on peptide manufacturing costs and formulation complexity.
• Mass administration routes. Water-soluble peptide formulations for drinking water medication or feed additives are preferred over individual animal injection for poultry and swine operations.

The FDA Center for Veterinary Medicine has approved fewer than 15 peptide-based veterinary drugs in the past two decades, despite peptides being the fastest-growing drug class in human medicine.

The INAD/NADA Regulatory Pathway

Veterinary drugs in the United States are regulated by the FDA Center for Veterinary Medicine (CVM) under a regulatory framework that differs from the human drug approval process in several important ways. Understanding this framework is essential for sponsors entering veterinary peptide drug development.

Investigational New Animal Drug (INAD) Application

The INAD is the veterinary equivalent of the human IND. Filing an INAD exemption allows sponsors to conduct clinical investigations of the peptide drug candidate in the target animal species. Key elements of the INAD include:

• Target animal safety data. Unlike human INDs, which rely primarily on preclinical animal models, veterinary INDs must include safety data in the actual target species. For a canine peptide drug, this means conducting safety studies in dogs, not just rodents.
• Environmental assessment. CVM requires an environmental assessment or claim of categorical exclusion for veterinary drugs, addressing potential environmental impact from drug residues excreted by treated animals.
• Chemistry, Manufacturing, and Controls. Similar to human drug CMC requirements, but with attention to formulation formats relevant to veterinary practice (chewable tablets, injectable solutions, pour-on formulations, intramammary infusions).

New Animal Drug Application (NADA)

The NADA is the veterinary equivalent of the human NDA. A complete NADA submission includes:

• Effectiveness data. Adequate and well-controlled clinical studies demonstrating that the peptide drug is effective for its intended use in the target species under actual or simulated field conditions.
• Target animal safety. Comprehensive safety data in the target species, including acute toxicity, target animal tolerance studies (typically at 1x, 3x, and 5x the proposed dose), and reproductive safety if applicable.
• Human food safety (for food animals). For peptide drugs used in food-producing animals, the NADA must include human food safety data demonstrating that residues in edible tissues do not pose a risk to consumers. This requires establishing a tolerance (maximum residue limit), an acceptable daily intake, and validated analytical methods for residue detection.
• Environmental safety. Environmental impact analysis addressing the fate and effects of the drug and its metabolites in the environment.
• Manufacturing information. Complete CMC data supporting commercial-scale manufacturing, stability, and quality control.

Minor Use/Minor Species (MUMS) Designation

For peptide drugs targeting rare conditions or minor species (such as zoo animals, ornamental fish, or minor livestock species), CVM's MUMS program provides incentives similar to the human orphan drug designation, including extended marketing exclusivity and potential for conditional approval based on a reduced data package.

The FDA Center for Veterinary Medicine has approved fewer than 10 peptide-based drugs for veterinary use, compared to more than 80 peptide therapeutics approved for human use. This disparity highlights both the regulatory learning curve for veterinary peptides and the opportunity for first movers in this space.

Large Animal vs. Small Animal Development: Key Differences

The practical differences between developing peptide drugs for large animals (horses, cattle) and small animals (dogs, cats) extend beyond formulation to encompass study design, manufacturing scale, and commercial strategy.

Study Design

• Large animal studies are logistically complex and expensive. Housing, feeding, and monitoring cattle or horses during clinical trials requires specialized facilities. Sample sizes are often smaller than in small animal studies, which affects statistical power and study design.
• Small animal studies benefit from larger available patient populations (particularly dogs) and the growing network of veterinary clinical trial sites at academic veterinary hospitals and specialty practices.

Manufacturing Scale

• Large animal formulations require higher per-dose peptide quantities due to larger body weights, which affects cost of goods and manufacturing batch size calculations.
• Small animal formulations may require multiple strengths or concentration-adjustable formats to accommodate the wide weight range across breeds.

Commercial Considerations

• Large animal markets (particularly cattle) are driven by herd economics, where treatment cost must be justified by improved productivity (milk yield, weight gain, reproductive performance). Per-dose pricing is constrained by the value of the individual animal.
• Small animal markets (particularly dogs) benefit from the humanization of pet care, where owners are increasingly willing to invest in advanced therapeutics for their companion animals. Per-dose pricing can reflect the value of the therapeutic benefit rather than the economic value of the animal.

When selecting a CRO for veterinary peptide development, verify that they have completed at least one INAD or NADA submission, not just general peptide synthesis experience, as the CVM's technical requirements for species-specific safety data differ significantly from CDER's human drug standards.

Why Outsource Veterinary Peptide Drug Development?

Most peptide-focused CROs and CDMOs have built their capabilities around human pharmaceutical development. Similarly, most veterinary pharmaceutical development organizations lack deep experience with peptide drug candidates. This capability gap makes outsourcing veterinary peptide drug development to partners with dual expertise particularly valuable.

An ideal outsourcing partner for veterinary peptide drug development should offer:

• Peptide synthesis and formulation. GMP peptide synthesis with the ability to develop species-specific formulations (injectable, oral, topical, intramammary) tailored to the target animal and clinical context.
• Target animal pharmacokinetics. PK study capabilities in the target species, including serial blood sampling, bioanalytical method development, and PK modeling.
• Target animal safety. GLP-compliant safety studies in the target species, including tolerance studies at multiples of the proposed therapeutic dose.
• Regulatory strategy. Experience with CVM's INAD/NADA framework, including pre-submission meetings, technical section preparation, and environmental assessment.
• Tissue residue studies (for food animals). Capability to conduct tissue residue depletion studies and develop validated analytical methods for peptide residue detection in edible tissues.
• Clinical trial management. Experience managing multi-site veterinary clinical trials, including site selection, investigator training, case report form design, and data management.

Emerging Opportunities in Veterinary Peptide Therapeutics

Several therapeutic areas are driving interest in veterinary peptide drug development:

• Canine and feline obesity. GLP-1 receptor agonists and dual agonist peptides are being explored for weight management in companion animals, mirroring the success of these agents in human medicine.
• Antimicrobial peptides. With growing concerns about antimicrobial resistance in livestock production, antimicrobial peptides represent an alternative to conventional antibiotics for treating bovine mastitis, swine respiratory infections, and poultry enteric diseases.
• Equine musculoskeletal conditions. Peptides targeting inflammatory mediators, cartilage repair, or pain signaling are being developed for osteoarthritis and soft tissue injuries in performance horses.
• Reproductive management. GnRH analogs and kisspeptin-based peptides are being evaluated for estrus synchronization and fertility enhancement in cattle and swine breeding programs.
• Oncology. As veterinary oncology becomes increasingly sophisticated, peptide-drug conjugates and targeted peptide therapeutics are being explored for canine cancers.

Frequently Asked Questions

How does the veterinary drug approval process differ from human drug approval? Veterinary drugs are regulated by the FDA Center for Veterinary Medicine (CVM) through the INAD/NADA pathway, which requires effectiveness and safety data in the actual target animal species rather than preclinical models. For food-producing animals, human food safety data (tissue residue studies) are also required. The overall timeline and cost are generally lower than for human drug approval, but the scientific and regulatory requirements are still substantial.

Can a human-approved peptide drug be directly repurposed for veterinary use? Not without modification. Species-specific differences in pharmacokinetics, receptor homology, and metabolic pathways mean that a human peptide drug may have different efficacy and safety profiles in veterinary species. Additionally, formulation requirements differ significantly between human and veterinary use. However, human-validated targets and peptide scaffolds can serve as starting points for veterinary drug development programs.

What are withdrawal periods, and why do they matter for veterinary peptide drugs? Withdrawal periods are the minimum time that must elapse between the last drug administration and the slaughter of a food-producing animal (or the collection of milk or eggs) to ensure that drug residues in edible tissues are below safe levels. Establishing withdrawal periods requires tissue residue depletion studies and is a mandatory component of the NADA for drugs used in food animals.

How long does it take to develop a veterinary peptide drug from concept to approval? Timelines vary widely depending on the target species, therapeutic indication, and regulatory pathway. A companion animal peptide drug (dog or cat) typically requires 5 to 8 years from concept to NADA approval. MUMS designation for minor species or minor uses can reduce this timeline through conditional approval provisions.

What should sponsors look for in an outsourcing partner for veterinary peptide drug development? Key capabilities include GMP peptide synthesis, species-specific formulation development, target animal PK and safety study capabilities, CVM regulatory expertise, and (for food animal applications) tissue residue study capabilities with validated bioanalytical methods. Experience managing veterinary clinical trials across multiple sites is also important for sponsors approaching the NADA stage.

Launch Your Veterinary Peptide Drug Program with PeptideStaff

The veterinary peptide therapeutics market is positioned for significant growth as animal health companies recognize the potential of peptides to address unmet needs in companion animal, equine, and livestock medicine. PeptideStaff connects sponsors with contract research and manufacturing partners who combine deep peptide science expertise with veterinary pharmaceutical development experience. Whether you are developing a GLP-1 analog for canine obesity, an antimicrobial peptide for bovine mastitis, or a targeted peptide therapeutic for equine osteoarthritis, our network can help you identify the right outsourcing partner to navigate species-specific formulation challenges and the INAD/NADA regulatory pathway. Contact PeptideStaff today to discuss your veterinary peptide drug development needs.